N. Yamamoto et al., Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol, J CL ONCOL, 18(11), 2000, pp. 2301-2308
Purpose: There is no simple and practical method for the estimation of the
interpatient variability of cytochrome P450 (CYP3A4) enzyme activity. Corti
sol is metabolized by this enzyme and excreted as 6-beta-hydroxycortisol (6
beta-OHF) and free-cortisol (FC) in urine, and docetaxel is also metaboliz
ed by hepatic CYP3A4 enzyme. We developed a new method for the estimation o
f CYP3A4 activity by measuring urinary cortisol metabolite after administra
tion of exogenous cortisol. This study was aimed at assessing the predictab
ility of the individual activity of CYP3A4 estimated by this method.
Patients and Methods: Thirty patients with advanced non-small-cell lung can
cer were entered onto this study. Hydrocortisone 300 mg was administered in
travenously, and urinary 6 beta-OHF and FC were measured, More than 2 days
later, 60 mg/m(2) of docetaxel was administered intravenously with pharmaco
kinetic sampling. The correlation between docetaxel pharmacokinetics and es
timated interpatient variability of CYP3A4 activity with the application of
our method was assessed,
Results: After cortisol administration, the total amount of 24-hour urinary
6 beta-OHF (T6 beta-OHF) increased about 60-fold compared with pretreatmen
t levels, averaging 12,273 +/- 4,076 mu g/d (mean +/- SD). Docetaxel cleara
nce (CL) and area under the concentration-time curve averaged 24.5 +/- 6.4
L/h/m(2) and 2.66 +/- 0.91 mg/L 8729 h, respectively. An excellent correlat
ion between docetaxel CL and T6 beta-OHF was observed (r = .867). In multiv
ariate analysis, T6 beta-OHF (P < .001), alpha-1-acid glycoprotein (P < .00
4), AST (P = .007), and age (P = .022) significantly correlated with doceta
xel CL.
Conclusion: The interpatient variability of CYP3A4 activity and docetaxel C
L could be predicted by measuring T6 beta-OHF after cortisol administration
. J Clin Oncol 18:2301-2308. (C) 2000 by American Society of Clinical Oncol
ogy.